226 related articles for article (PubMed ID: 20959535)
1. Multi-tissue, selective PPARγ modulation of insulin sensitivity and metabolic pathways in obese rats.
Hsiao G; Chapman J; Ofrecio JM; Wilkes J; Resnik JL; Thapar D; Subramaniam S; Sears DD
Am J Physiol Endocrinol Metab; 2011 Jan; 300(1):E164-74. PubMed ID: 20959535
[TBL] [Abstract][Full Text] [Related]
2. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
Rasouli N; Kern PA; Elbein SC; Sharma NK; Das SK
Pharmacogenet Genomics; 2012 Jul; 22(7):484-97. PubMed ID: 22437669
[TBL] [Abstract][Full Text] [Related]
3. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
[TBL] [Abstract][Full Text] [Related]
4. PPARγ is a major regulator of branched-chain amino acid blood levels and catabolism in white and brown adipose tissues.
Blanchard PG; Moreira RJ; Castro É; Caron A; Côté M; Andrade ML; Oliveira TE; Ortiz-Silva M; Peixoto AS; Dias FA; Gélinas Y; Guerra-Sá R; Deshaies Y; Festuccia WT
Metabolism; 2018 Dec; 89():27-38. PubMed ID: 30316815
[TBL] [Abstract][Full Text] [Related]
5. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
6. In vivo multi-tissue efficacy of peroxisome proliferator-activated receptor-γ therapy on glucose and fatty acid metabolism in obese type 2 diabetic rats.
Nemanich S; Rani S; Shoghi K
Obesity (Silver Spring); 2013 Dec; 21(12):2522-9. PubMed ID: 23512563
[TBL] [Abstract][Full Text] [Related]
7. A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice.
Wu D; Eeda V; Undi RB; Mann S; Stout M; Lim HY; Wang W
Mol Metab; 2021 Dec; 54():101363. PubMed ID: 34710641
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.
Chen Z; Vigueira PA; Chambers KT; Hall AM; Mitra MS; Qi N; McDonald WG; Colca JR; Kletzien RF; Finck BN
J Biol Chem; 2012 Jul; 287(28):23537-48. PubMed ID: 22621923
[TBL] [Abstract][Full Text] [Related]
9. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
[TBL] [Abstract][Full Text] [Related]
10. Regulation of adipose branched-chain amino acid catabolism enzyme expression and cross-adipose amino acid flux in human obesity.
Lackey DE; Lynch CJ; Olson KC; Mostaedi R; Ali M; Smith WH; Karpe F; Humphreys S; Bedinger DH; Dunn TN; Thomas AP; Oort PJ; Kieffer DA; Amin R; Bettaieb A; Haj FG; Permana P; Anthony TG; Adams SH
Am J Physiol Endocrinol Metab; 2013 Jun; 304(11):E1175-87. PubMed ID: 23512805
[TBL] [Abstract][Full Text] [Related]
11. PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization.
Sugii S; Olson P; Sears DD; Saberi M; Atkins AR; Barish GD; Hong SH; Castro GL; Yin YQ; Nelson MC; Hsiao G; Greaves DR; Downes M; Yu RT; Olefsky JM; Evans RM
Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22504-9. PubMed ID: 20018750
[TBL] [Abstract][Full Text] [Related]
12. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM
Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
[TBL] [Abstract][Full Text] [Related]
13. Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice.
Lee DH; Huang H; Choi K; Mantzoros C; Kim YB
Am J Physiol Endocrinol Metab; 2012 Mar; 302(5):E552-60. PubMed ID: 22215652
[TBL] [Abstract][Full Text] [Related]
14. Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.
Dallaire P; Bellmann K; Laplante M; Gélinas S; Centeno-Baez C; Penfornis P; Peyot ML; Latour MG; Lamontagne J; Trujillo ME; Scherer PE; Prentki M; Deshaies Y; Marette A
Diabetes; 2008 Aug; 57(8):1999-2011. PubMed ID: 18458147
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation.
Hallakou S; Foufelle F; Doaré L; Kergoat M; Ferré P
Diabetologia; 1998 Aug; 41(8):963-8. PubMed ID: 9726600
[TBL] [Abstract][Full Text] [Related]
16. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action.
Zierath JR; Ryder JW; Doebber T; Woods J; Wu M; Ventre J; Li Z; McCrary C; Berger J; Zhang B; Moller DE
Endocrinology; 1998 Dec; 139(12):5034-41. PubMed ID: 9832442
[TBL] [Abstract][Full Text] [Related]
17. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
[TBL] [Abstract][Full Text] [Related]
18. Effects of pioglitazone on stearoyl-CoA desaturase in obese Zucker fa/fa rats.
Toyama T; Kudo N; Hibino Y; Mitsumoto A; Nishikawa M; Kawashima Y
J Pharmacol Sci; 2007 Jun; 104(2):137-45. PubMed ID: 17538229
[TBL] [Abstract][Full Text] [Related]
19. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats.
Li J; Xue YM; Zhu B; Pan YH; Zhang Y; Wang C; Li Y
J Diabetes Res; 2018; 2018():4627842. PubMed ID: 30225267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
